- Home
- CELC vs ZVRA Comparison
CELC vs ZVRA Comparison
Compare CELC & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- ZVRA
- Stock Information
- Founded
- CELC 2011
- ZVRA 2006
- Country
- CELC United States
- ZVRA United States
- Employees
- CELC N/A
- ZVRA N/A
- Industry
- CELC Medical Specialities
- ZVRA Biotechnology: Pharmaceutical Preparations
- Sector
- CELC Health Care
- ZVRA Health Care
- Exchange
- CELC Nasdaq
- ZVRA Nasdaq
- Market Cap
- CELC 489.7M
- ZVRA 511.6M
- IPO Year
- CELC 2017
- ZVRA 2015
- Fundamental
- Price
- CELC $12.86
- ZVRA $8.52
- Analyst Decision
- CELC Strong Buy
- ZVRA Strong Buy
- Analyst Count
- CELC 6
- ZVRA 7
- Target Price
- CELC $29.17
- ZVRA $21.20
- AVG Volume (30 Days)
- CELC 232.9K
- ZVRA 443.1K
- Earning Date
- CELC 11-14-2024
- ZVRA 11-12-2024
- Dividend Yield
- CELC N/A
- ZVRA N/A
- EPS Growth
- CELC N/A
- ZVRA N/A
- EPS
- CELC N/A
- ZVRA N/A
- Revenue
- CELC N/A
- ZVRA $24,489,000.00
- Revenue This Year
- CELC N/A
- ZVRA N/A
- Revenue Next Year
- CELC N/A
- ZVRA $376.61
- P/E Ratio
- CELC N/A
- ZVRA N/A
- Revenue Growth
- CELC N/A
- ZVRA 47.85
- 52 Week Low
- CELC $11.51
- ZVRA $4.20
- 52 Week High
- CELC $22.19
- ZVRA $9.76
- Technical
- Relative Strength Index (RSI)
- CELC 42.58
- ZVRA 44.64
- Support Level
- CELC $11.94
- ZVRA $8.28
- Resistance Level
- CELC $13.14
- ZVRA $8.79
- Average True Range (ATR)
- CELC 0.51
- ZVRA 0.36
- MACD
- CELC 0.07
- ZVRA -0.11
- Stochastic Oscillator
- CELC 58.70
- ZVRA 20.07
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.